or Try an Advanced Search...

    Resistant Prostate Cancer Stocks List

    Symbol Grade Name % Change
    AMGN B Amgen Inc. 2.10
    EXEL D Exelixis, Inc. 0.79
    CRDF D Cardiff Oncology, Inc. 5.63
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
    Related Stock Lists: Prostate Cancer Biotechnology Cancer Drugs Medicine Metastatic Castration Resistant Prostate Cancer Acute Myeloid Leukemia Adenosine Advanced Solid Tumors Antineoplastic Drugs Blood Cells Bone Bone Disease Cancer Care Cancer Treatment Chemotherapy Clinic Clinical Medicine Colorectal Cancer Cyclopropanes

    Related ETFs - A few ETFs which own one or more of the above listed Resistant Prostate Cancer stocks.

    Symbol Grade Name Weight
    BBH C Market Vectors Biotech ETF 15.02
    IBB D iShares Nasdaq Biotechnology Index Fund 9.29
    IBBQ C Invesco Nasdaq Biotechnology ETF 9.28
    BIS D ProShares UltraShort Nasdaq Biotechnology 8.87
    PBE C PowerShares Dynamic Biotech & Genome 7.88
    View all Resistant Prostate Cancer ETFs...
    Compare ETFs
    Compare BIS to PBE Compare IBB to BIS Compare IBBQ to PBE

        Resistant Prostate Cancer Stocks Recent News

        Date Stock Title
        May 9 AMGN CytomX slides after early data for Amgen-partnered cancer drug
        May 9 AMGN Q1 2024 CytomX Therapeutics Inc Earnings Call
        May 7 EXEL Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
        May 7 AMGN 15 Best S&P 500 Dividend Stocks To Buy Now
        May 6 EXEL Exelixis (EXEL) International Revenue Performance Explored
        May 6 AMGN Investors Pile Into Amgen in Search of Next Obesity Drug Payout
        May 5 AMGN Cathie Wood's Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity Pipeline Update
        May 4 AMGN Amgen First Quarter 2024 Earnings: EPS Misses Expectations
        May 4 AMGN Amgen Could Become A Real Contender In The Obesity Market
        May 4 CRDF Cardiff Oncology First Quarter 2024 Earnings: Beats Expectations
        May 4 AMGN Decoding Amgen Inc (AMGN): A Strategic SWOT Insight
        May 3 AMGN Why Amgen Stock Zoomed Nearly 12% Higher Today
        May 3 AMGN Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
        May 3 AMGN Analyst unveils Amgen stock price target after weight-loss drug data
        May 3 AMGN Amgen's Q1 Earnings: Solid All Court Progress, Major Weight Loss Catalyst Pending
        May 3 AMGN Interest rate cuts could switch ‘from stroll to a sprint’ after US jobs surprise
        May 3 AMGN William Blair, Barclays upgrade Amgen following GLP-1 drug update
        May 3 AMGN Top Midday Stories: Apple's Dividend, Buybacks Announcements; Amgen Obesity Drug Trial Results; Exxon Completes Pioneer Acquisition
        May 3 AMGN US STOCKS-Wall St rallies after soft jobs data allays rate jitters
        May 3 AMGN Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
        Related Stock Lists: Prostate Cancer Biotechnology Cancer Drugs Medicine Metastatic Castration Resistant Prostate Cancer Acute Myeloid Leukemia Adenosine Advanced Solid Tumors Antineoplastic Drugs Blood Cells Bone Bone Disease Cancer Care Cancer Treatment Chemotherapy Clinic Clinical Medicine Colorectal Cancer Cyclopropanes
        Resistant Prostate Cancer

        Resistant prostate cancer is a type of prostate cancer that has become resistant to hormone therapy, which is the most common form of treatment for prostate cancer. This type of cancer is more difficult to treat and may require more aggressive treatments such as chemotherapy or radiation therapy.

        Browse All Tags